Epigenetic Modification in Systemic Rheumatic Diseases.
10.4078/jrd.2013.20.3.140
- Author:
Jennifer LEE
1
;
Hae Rim KIM
;
Sang Heon LEE
;
Ho Youn KIM
Author Information
1. Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
- Publication Type:Review
- Keywords:
Epigenomics;
DNA methylation;
Histone code;
MicroRNAs;
Autoimmune diseases
- MeSH:
Autoimmune Diseases;
Base Sequence;
Biomarkers;
Cell Differentiation;
Diet;
Disease Progression;
DNA;
DNA Methylation;
DNA Repair;
Epigenomics;
Fibroblasts;
Gene Expression;
Histone Code;
Histones;
Humans;
Mass Screening;
MicroRNAs;
Nucleosomes;
Rheumatic Diseases;
RNA, Messenger;
T-Lymphocytes
- From:Journal of Rheumatic Diseases
2013;20(3):140-148
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Epigenetics is defined as an inheritable effect that influences gene activity, but does not involve a change in DNA sequence. Epigenetic gene regulation has an essential role in determining individual gene function and activity in each specific cell type. Epigenetics includes four predominant mechanisms: DNA methylation, histone modification, nucleosome positioning and microRNA (miRNA). These mechanisms influence gene expression, cell differentiation, proliferation, DNA repair and replication. Epigenetic modifications are far more sensitive to environmental stimuli than DNA sequence alterations. Candidate gene approaches have identified a small set of genes that undergo epigenetic changes, such as aberrant DNA demethylation, histone modification, as well as regulation by miRNA in rheumatic diseases. It is well known that T cells from patients with SLE or RA, as well as synovial fibroblasts from individuals with RA, have sequences undergoing DNA hypomethylation and/or histone modifications. In addition, miRNA regulates the gene expression by pairing with its target mRNAs and is often deregulated in systemic rheumatic diseases. High-throughput approaches are necessary for screening the epigenetic alterations, and it is essential to screen the specific tissue and cell types that are relevant to the disease pathogenesis. Identification of cell-specific targets of the epigenetic deregulation in rheumatic disorders will provide clinical markers for the diagnosis, disease progression and response to therapy. Our understanding of epigenetics is in its infancy. New generation of pharmaceuticals, which manipulate the epigenome to the switch targeted genes on or off are under investigation. The new field of repairing or optimizing the epigenome through epigenetic modifier and/or diet is wide open.
